Literature DB >> 30849478

Downregulation of tumor suppressor RACK1 by Helicobacter pylori infection promotes gastric carcinogenesis through the integrin β-1/NF-κB signaling pathway.

Yi Hu1, Jian-Ping Liu2, Xue-Yang Li3, Yan Cai4, Cong He5, Nian-Shuang Li6, Chuan Xie7, Zhi-Juan Xiong8, Zhong-Ming Ge9, Nong-Hua Lu10, Yin Zhu11.   

Abstract

Receptor of activated protein kinase C 1 (RACK1) is downregulated in gastric cancer and is involved in modulating NF-κB signaling pathway activity. However, the underlying molecular mechanisms regulating RACK1 expression are unclear. In this study, we demonstrated that downregulated expression of RACK1 was observed in gastric cancer tissue compared to adjacent normal tissue and was correlated with poor prognosis in patients. Helicobacter pylori (H. pylori) infection downregulated RACK1 expression in concert with canonical NF-κB signaling pathway activation in vivo and in vitro. RACK1 overexpression suppressed NF-κB signaling pathway activation as well as the release of downstream proinflammatory cytokines. In addition, RACK1 downregulation increased integrin β-1 expression, while integrin β-1 silencing decreased NF-κB signaling activation. Moreover, H. pylori infection downregulated RACK1 but upregulated integrin β-1 expression at the precancerous lesion stages in human subjects. Our data indicate that H. pylori infection promotes the upregulation of integrin β-1 expression via downregulation of RACK1 expression, which subsequently leads to the elevated activation of the NF-κB signaling pathway, an essential step in H. pylori-induced carcinogenesis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gastric cancer; Helicobacter pylori; Integrin β-1; NF-κB; RACK1

Mesh:

Substances:

Year:  2019        PMID: 30849478     DOI: 10.1016/j.canlet.2019.02.039

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.

Authors:  Boyan Huang; Peiqiang Mu; Yan Yu; Wenya Zhu; Tianqing Jiang; Rong Deng; Gongkan Feng; Jikai Wen; Xiaofeng Zhu; Yiqun Deng
Journal:  Gastric Cancer       Date:  2020-06-11       Impact factor: 7.370

2.  Inhibition of autophagy aggravates DNA damage response and gastric tumorigenesis via Rad51 ubiquitination in response to H. pylori infection.

Authors:  Chuan Xie; Nianshuang Li; Huan Wang; Cong He; Yi Hu; Chao Peng; Yaobin Ouyang; Dejie Wang; Yong Xie; Jiang Chen; Xu Shu; Yin Zhu; Nonghua Lu
Journal:  Gut Microbes       Date:  2020-06-26

3.  P76RBE silencing inhibits ovarian cancer cell proliferation, migration, and invasion via suppressing the integrin β1/NF-κB pathway.

Authors:  Limei Yan; Zeping He; Wei Li; Ning Liu; Song Gao
Journal:  Cell Cycle       Date:  2021-08-12       Impact factor: 5.173

4.  Integrative Analysis of Differential lncRNA/mRNA Expression Profiling in Helicobacter pylori Infection-Associated Gastric Carcinogenesis.

Authors:  Nianshuang Li; Yaobin Ouyang; Sihai Chen; Chao Peng; Cong He; Junbo Hong; Xiaoyu Yang; Yin Zhu; Nong-Hua Lu
Journal:  Front Microbiol       Date:  2020-05-08       Impact factor: 5.640

5.  Gastro-Protective Effects of Calycosin Against Precancerous Lesions of Gastric Carcinoma in Rats.

Authors:  Danyan Li; Luqing Zhao; Yuxin Li; Xiuhong Kang; Shengsheng Zhang
Journal:  Drug Des Devel Ther       Date:  2020-06-09       Impact factor: 4.162

Review 6.  Gastric Cancer: Advances in Carcinogenesis Research and New Therapeutic Strategies.

Authors:  Lornella Seeneevassen; Emilie Bessède; Francis Mégraud; Philippe Lehours; Pierre Dubus; Christine Varon
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

7.  PHB2 promotes tumorigenesis via RACK1 in non-small cell lung cancer.

Authors:  Bin Wu; Ning Chang; Hangtian Xi; Jie Xiong; Ying Zhou; Yingtong Wu; Shuo Wu; Ning Wang; Hongyu Yi; Yun Song; Lihua Chen; Jian Zhang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.